40 results on '"Sharp TE"'
Search Results
2. Adjunctive therapy with an oral H 2 S donor provides additional therapeutic benefit beyond SGLT2 inhibition in cardiometabolic heart failure with preserved ejection fraction.
- Author
-
Doiron JE, Xia H, Yu X, Nevins AR, LaPenna KB, Sharp TE 3rd, Goodchild TT, Allerton TD, Elgazzaz M, Lazartigues E, Shah SJ, Li Z, and Lefer DJ
- Abstract
Background and Purpose: Sodium glucose cotransporter 2 inhibitors (SGLT2i) have emerged as a potent therapy for heart failure with preserved ejection fraction (HFpEF). Hydrogen sulphide (H
2 S), a well-studied cardioprotective agent, could be beneficial in HFpEF. SGLT2i monotherapy and combination therapy involving an SGLT2i and H2 S donor in two preclinical models of cardiometabolic HFpEF was investigated., Experimental Approach: Nine-week-old C57BL/6N mice received L-NAME and a 60% high fat diet for five weeks. Mice were then randomized to either control, SGLT2i monotherapy or SGLT2i and H2 S donor, SG1002, for five additional weeks. Ten-week-old ZSF1 obese rats were randomized to control, SGLT2i or SGLT2i and SG1002 for 8 weeks. SG1002 monotherapy was investigated in additional animals. Cardiac function (echocardiography and haemodynamics), exercise capacity, glucose handling and multiorgan pathology were monitored during experimental protocols., Key Results: SGLT2i treatment improved E/e' ratio and treadmill exercise in both models. Combination therapy afforded increases in cardiovascular sulphur bioavailability that coincided with improved left end-diastolic function (E/e' ratio), exercise capacity, metabolic state, cardiorenal fibrosis, and hepatic steatosis. Follow-up studies with SG1002 monotherapy revealed improvements in diastolic function, exercise capacity and multiorgan histopathology., Conclusions and Implications: SGLT2i monotherapy remediated pathological complications exhibited by two well-established HFpEF models. Adjunctive H2 S therapy resulted in further improvements of cardiometabolic perturbations beyond SGLT2i monotherapy. Follow-up SG1002 monotherapy studies inferred an improved phenotype with combination therapy beyond either monotherapy. These data demonstrate the differing effects of SGLT2i and H2 S therapy while also revealing the superior efficacy of the combination therapy in cardiometabolic HFpEF., (© 2024 The Author(s). British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.)- Published
- 2024
- Full Text
- View/download PDF
3. Early Renal Denervation Attenuates Cardiac Dysfunction in Heart Failure With Preserved Ejection Fraction.
- Author
-
Doiron JE, Li Z, Yu X, LaPenna KB, Quiriarte H, Allerton TD, Koul K, Malek A, Shah SJ, Sharp TE, Goodchild TT, Kapusta DR, and Lefer DJ
- Subjects
- Humans, Male, Rats, Animals, Stroke Volume, Tyrosine 3-Monooxygenase metabolism, Kidney metabolism, Sympathectomy methods, Inflammation metabolism, Norepinephrine, Fibrosis, Denervation, Heart Failure metabolism
- Abstract
Background: The renal sympathetic nervous system modulates systemic blood pressure, cardiac performance, and renal function. Pathological increases in renal sympathetic nerve activity contribute to the pathogenesis of heart failure with preserved ejection fraction (HFpEF). We investigated the effects of renal sympathetic denervation performed at early or late stages of HFpEF progression., Methods and Results: Male ZSF1 obese rats were subjected to radiofrequency renal denervation (RF-RDN) or sham procedure at either 8 weeks or 20 weeks of age and assessed for cardiovascular function, exercise capacity, and cardiorenal fibrosis. Renal norepinephrine and renal nerve tyrosine hydroxylase staining were performed to quantify denervation following RF-RDN. In addition, renal injury, oxidative stress, inflammation, and profibrotic biomarkers were evaluated to determine pathways associated with RDN. RF-RDN significantly reduced renal norepinephrine and tyrosine hydroxylase content in both study cohorts. RF-RDN therapy performed at 8 weeks of age attenuated cardiac dysfunction, reduced cardiorenal fibrosis, and improved endothelial-dependent vascular reactivity. These improvements were associated with reductions in renal injury markers, expression of renal NLR family pyrin domain containing 3/interleukin 1β, and expression of profibrotic mediators. RF-RDN failed to exert beneficial effects when administered in the 20-week-old HFpEF cohort., Conclusions: Our data demonstrate that early RF-RDN therapy protects against HFpEF disease progression in part due to the attenuation of renal fibrosis and inflammation. In contrast, the renoprotective and left ventricular functional improvements were lost when RF-RDN was performed in later HFpEF progression. These results suggest that RDN may be a viable treatment option for HFpEF during the early stages of this systemic inflammatory disease.
- Published
- 2024
- Full Text
- View/download PDF
4. Common Heart Failure With Preserved Ejection Fraction Animal Models Yield Disparate Myofibril Mechanics.
- Author
-
Fenwick AJ, Jani VP, Foster DB, Sharp TE, Goodchild TT, LaPenna K, Doiron JE, Lefer DJ, Hill JA, Kass DA, and Cammarato A
- Subjects
- Animals, Stroke Volume, Ventricular Function, Left, Models, Animal, Myofibrils, Heart Failure
- Published
- 2024
- Full Text
- View/download PDF
5. Cardiovascular dysfunction induced by combined exposure to nicotine inhalation and high-fat diet.
- Author
-
Whitehead AK, Li Z, LaPenna KB, Abbes N, Sharp TE, Lefer DJ, Lazartigues E, and Yue X
- Subjects
- Humans, Female, Mice, Male, Animals, Nicotine toxicity, Mice, Inbred C57BL, Vasodilation, Blood Pressure, Diet, High-Fat adverse effects, Ventricular Dysfunction, Left chemically induced
- Abstract
Smoking and high-fat diet (HFD) consumption are two modifiable risk factors for cardiovascular (CV) diseases, and individuals who are overweight or obese due to unhealthy diet are more likely to use tobacco products. In this study, we aim to investigate the combined effects of nicotine (the addictive component of all tobacco products) and HFD on CV health, which are poorly understood. C57BL/6N male mice were placed on either HFD (60 kcal% fat) or regular diet (22 kcal% fat) and exposed to air or nicotine vapor for 10-12 wk. CV function was monitored by echocardiography and radiotelemetry, with left ventricular (LV) catheterization and aortic ring vasoreactivity assays performed at end point. Mice on HFD exhibited increased heart rate and impaired parasympathetic tone, whereas nicotine exposure increased sympathetic vascular tone as evidenced by increased blood pressure (BP) response to ganglionic blockade. Although neither nicotine nor HFD alone or in combination significantly altered BP, nicotine exposure disrupted circadian BP regulation with reduced BP dipping. LV catheterization revealed that combined exposure to nicotine and HFD led to LV diastolic dysfunction with increased LV end-diastolic pressure (LVEDP). Moreover, combined exposure resulted in increased inhibitory phosphorylation of endothelial nitric oxide synthase and greater impairment of endothelium-dependent vasodilation. Finally, a small cohort of C57BL/6N females with combined exposure exhibited similar increases in LVEDP, indicating that both sexes are susceptible to the combined effect of nicotine and HFD. In summary, combined exposure to nicotine and HFD leads to greater CV harm, including both additive and new-onset CV dysfunction. NEW & NOTEWORTHY Nicotine product usage and high-fat diet consumption are two modifiable risk factors for cardiovascular diseases. Here, we demonstrate that in mice, combined exposure to inhaled nicotine and high-fat diet results in unique cardiovascular consequences compared with either treatment alone, including left ventricular diastolic dysfunction, dysregulation of blood pressure, autonomic dysfunction, and greater impairment of endothelium-dependent vasorelaxation. These findings indicate that individuals who consume both nicotine products and high-fat diet have distinctive cardiovascular risks.
- Published
- 2024
- Full Text
- View/download PDF
6. Combination Sodium Nitrite and Hydralazine Therapy Attenuates Heart Failure With Preserved Ejection Fraction Severity in a "2-Hit" Murine Model.
- Author
-
LaPenna KB, Li Z, Doiron JE, Sharp TE 3rd, Xia H, Moles K, Koul K, Wang JS, Polhemus DJ, Goodchild TT, Patel RB, Shah SJ, and Lefer DJ
- Subjects
- Mice, Male, Animals, Sodium Nitrite, Stroke Volume physiology, NG-Nitroarginine Methyl Ester, Disease Models, Animal, Mice, Inbred C57BL, Hydralazine pharmacology, Nitric Oxide Synthase, Heart Failure drug therapy, Drinking Water
- Abstract
Background Recent studies have suggested that cardiac nitrosative stress mediated by pathological overproduction of nitric oxide (NO) via inducible NO synthase (iNOS) contributes to the pathogenesis of heart failure with preserved ejection fraction (HFpEF). Other studies have suggested that endothelial NO synthase (eNOS) dysfunction and attenuated NO bioavailability contribute to HFpEF morbidity and mortality. We sought to further investigate dysregulated NO signaling and to examine the effects of a NO-based dual therapy (sodium nitrite+hydralazine) following the onset of HFpEF using a "2-hit" murine model. Methods and Results Nine-week-old male C57BL/6 N mice (n=15 per group) were treated concurrently with high-fat diet and N(ω)-nitro-L-arginine methyl ester (L-NAME) (0.5 g/L per day) via drinking water for 10 weeks. At week 5, mice were randomized into either vehicle (normal saline) or combination treatment with sodium nitrite (75 mg/L in the drinking water) and hydralazine (2.0 mg/kg IP, BID). Cardiac structure and function were monitored with echocardiography and invasive hemodynamic measurements. Cardiac mitochondrial respiration, aortic vascular function, and exercise performance were also evaluated. Circulating and myocardial nitrite were measured to determine the bioavailability of NO. Circulating markers of oxidative or nitrosative stress as well as systemic inflammation were also determined. Severe HFpEF was evident by significantly elevated E/E', LVEDP, and Tau in mice treated with L-NAME and HFD, which was associated with impaired NO bioavailability, mitochondrial respiration, aortic vascular function, and exercise capacity. Treatment with sodium nitrite and hydralazine restored NO bioavailability, reduced oxidative and nitrosative stress, preserved endothelial function and mitochondrial respiration, limited the fibrotic response, and improved exercise capacity, ultimately attenuating the severity of "two-hit" HFpEF. Conclusions Our data demonstrate that nitrite, a well-established biomarker of NO bioavailability and a physiological source of NO, is significantly reduced in the heart and circulation in the "2-hit" mouse HFpEF model. Furthermore, sodium nitrite+hydralazine combined therapy significantly attenuated the severity of HFpEF in the "2-hit" cardiometabolic HFpEF. These data suggest that supplementing NO-based therapeutics with a potent antioxidant and vasodilator agent may result in synergistic benefits for the treatment of HFpEF.
- Published
- 2023
- Full Text
- View/download PDF
7. Hydrogen Sulfide Modulates Endothelial-Mesenchymal Transition in Heart Failure.
- Author
-
Li Z, Xia H, Sharp TE 3rd, LaPenna KB, Katsouda A, Elrod JW, Pfeilschifter J, Beck KF, Xu S, Xian M, Goodchild TT, Papapetropoulos A, and Lefer DJ
- Subjects
- Mice, Animals, Endothelial Cells metabolism, Nitric Oxide metabolism, Mice, Knockout, Endothelium, Vascular metabolism, Fibrosis, Hydrogen Sulfide metabolism, Heart Failure, Ventricular Dysfunction, Left
- Abstract
Background: Hydrogen sulfide is a critical endogenous signaling molecule that exerts protective effects in the setting of heart failure. Cystathionine γ-lyase (CSE), 1 of 3 hydrogen-sulfide-producing enzyme, is predominantly localized in the vascular endothelium. The interaction between the endothelial CSE-hydrogen sulfide axis and endothelial-mesenchymal transition, an important pathological process contributing to the formation of fibrosis, has yet to be investigated., Methods: Endothelial-cell-specific CSE knockout and Endothelial cell-CSE overexpressing mice were subjected to transverse aortic constriction to induce heart failure with reduced ejection fraction. Cardiac function, vascular reactivity, and treadmill exercise capacity were measured to determine the severity of heart failure. Histological and gene expression analyses were performed to investigate changes in cardiac fibrosis and the activation of endothelial-mesenchymal transition., Results: Endothelial-cell-specific CSE knockout mice exhibited increased endothelial-mesenchymal transition and reduced nitric oxide bioavailability in the myocardium, which was associated with increased cardiac fibrosis, impaired cardiac and vascular function, and worsened exercise performance. In contrast, genetic overexpression of CSE in endothelial cells led to increased myocardial nitric oxide, decreased endothelial-mesenchymal transition and cardiac fibrosis, preserved cardiac and endothelial function, and improved exercise capacity., Conclusions: Our data demonstrate that endothelial CSE modulates endothelial-mesenchymal transition and ameliorate the severity of pressure-overload-induced heart failure, in part, through nitric oxide-related mechanisms. These data further suggest that endothelium-derived hydrogen sulfide is a potential therapeutic for the treatment of heart failure with reduced ejection fraction.
- Published
- 2023
- Full Text
- View/download PDF
8. Mitochondrial H 2 S Regulates BCAA Catabolism in Heart Failure.
- Author
-
Li Z, Xia H, Sharp TE 3rd, LaPenna KB, Elrod JW, Casin KM, Liu K, Calvert JW, Chau VQ, Salloum FN, Xu S, Xian M, Nagahara N, Goodchild TT, and Lefer DJ
- Subjects
- Adenosine Triphosphate metabolism, Amino Acids, Branched-Chain metabolism, Animals, Humans, Mice, Mice, Inbred C57BL, Mitochondria metabolism, Myocardium metabolism, Heart Failure metabolism, Hydrogen Sulfide metabolism, Ventricular Dysfunction, Left metabolism
- Abstract
Background: Hydrogen sulfide (H
2 S) exerts mitochondria-specific actions that include the preservation of oxidative phosphorylation, biogenesis, and ATP synthesis, while inhibiting cell death. 3-MST (3-mercaptopyruvate sulfurtransferase) is a mitochondrial H2 S-producing enzyme whose functions in the cardiovascular disease are not fully understood. In the current study, we investigated the effects of global 3-MST deficiency in the setting of pressure overload-induced heart failure., Methods: Human myocardial samples obtained from patients with heart failure undergoing cardiac surgeries were probed for 3-MST protein expression. 3-MST knockout mice and C57BL/6J wild-type mice were subjected to transverse aortic constriction to induce pressure overload heart failure with reduced ejection fraction. Cardiac structure and function, vascular reactivity, exercise performance, mitochondrial respiration, and ATP synthesis efficiency were assessed. In addition, untargeted metabolomics were utilized to identify key pathways altered by 3-MST deficiency., Results: Myocardial 3-MST was significantly reduced in patients with heart failure compared with nonfailing controls. 3-MST KO mice exhibited increased accumulation of branched-chain amino acids in the myocardium, which was associated with reduced mitochondrial respiration and ATP synthesis, exacerbated cardiac and vascular dysfunction, and worsened exercise performance following transverse aortic constriction. Restoring myocardial branched-chain amino acid catabolism with 3,6-dichlorobenzo1[b]thiophene-2-carboxylic acid (BT2) and administration of a potent H2 S donor JK-1 ameliorates the detrimental effects of 3-MST deficiency in heart failure with reduced ejection fraction., Conclusions: Our data suggest that 3-MST derived mitochondrial H2 S may play a regulatory role in branched-chain amino acid catabolism and mediate critical cardiovascular protection in heart failure.- Published
- 2022
- Full Text
- View/download PDF
9. Alpha7 nicotinic acetylcholine receptor mediates chronic nicotine inhalation-induced cardiopulmonary dysfunction.
- Author
-
Whitehead AK, Fried ND, Li Z, Neelamegam K, Pearson CS, LaPenna KB, Sharp TE, Lefer DJ, Lazartigues E, Gardner JD, and Yue X
- Subjects
- Acetylcholine metabolism, Administration, Inhalation, Animals, Aorta, Thoracic drug effects, Female, Male, Mice, Pulmonary Artery drug effects, Up-Regulation, Vasodilation drug effects, Nicotine administration & dosage, alpha7 Nicotinic Acetylcholine Receptor genetics, alpha7 Nicotinic Acetylcholine Receptor metabolism
- Abstract
Cigarette smoking remains the leading modifiable risk factor for cardiopulmonary diseases; however, the effects of nicotine alone on cardiopulmonary function remain largely unknown. Previously, we have shown that chronic nicotine vapor inhalation in mice leads to the development of pulmonary hypertension (PH) with right ventricular (RV) remodeling. The present study aims to further examine the cardiopulmonary effects of nicotine and the role of the α7 nicotinic acetylcholine receptor (α7-nAChR), which is widely expressed in the cardiovascular system. Wild-type (WT) and α7-nAChR knockout (α7-nAChR-/-) mice were exposed to room air (control) or nicotine vapor daily for 12 weeks. Consistent with our previous study, echocardiography and RV catheterization reveal that male WT mice developed increased RV systolic pressure with RV hypertrophy and dilatation following 12-week nicotine vapor exposure; in contrast, these changes were not observed in male α7-nAChR-/- mice. In addition, chronic nicotine inhalation failed to induce PH and RV remodeling in female mice regardless of genotype. The effects of nicotine on the vasculature were further examined in male mice. Our results show that chronic nicotine inhalation led to impaired acetylcholine-mediated vasodilatory response in both thoracic aortas and pulmonary arteries, and these effects were accompanied by altered endothelial nitric oxide synthase phosphorylation (enhanced inhibitory phosphorylation at threonine 495) and reduced plasma nitrite levels in WT but not α7-nAChR-/- mice. Finally, RNA sequencing revealed up-regulation of multiple inflammatory pathways in thoracic aortas from WT but not α7-nAChR-/- mice. We conclude that the α7-nAChR mediates chronic nicotine inhalation-induced PH, RV remodeling and vascular dysfunction., (© 2022 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.)
- Published
- 2022
- Full Text
- View/download PDF
10. Reply: Tolerating Large Preclinical Models of HFpEF But Without the Intolerance?
- Author
-
Sharp TE, Lefer DJ, and Goodchild TT
- Published
- 2021
- Full Text
- View/download PDF
11. Renal Denervation to Treat Heart Failure.
- Author
-
Sharp TE 3rd and Lefer DJ
- Subjects
- Animals, Disease Progression, Heart Failure physiopathology, Humans, Kidney physiopathology, Heart Failure therapy, Sympathectomy methods
- Abstract
Heart failure (HF) is a global pandemic with a poor prognosis after hospitalization. Despite HF syndrome complexities, evidence of significant sympathetic overactivity in the manifestation and progression of HF is universally accepted. Confirmation of this dogma is observed in guideline-directed use of neurohormonal pharmacotherapies as a standard of care in HF. Despite reductions in morbidity and mortality, a growing patient population is resistant to these medications, while off-target side effects lead to dismal patient adherence to lifelong drug regimens. Novel therapeutic strategies, devoid of these limitations, are necessary to attenuate the progression of HF pathophysiology while continuing to reduce morbidity and mortality. Renal denervation is an endovascular procedure, whereby the ablation of renal nerves results in reduced renal afferent and efferent sympathetic nerve activity in the kidney and globally. In this review, we discuss the current state of preclinical and clinical research related to renal sympathetic denervation to treat HF.
- Published
- 2021
- Full Text
- View/download PDF
12. Novel Göttingen Miniswine Model of Heart Failure With Preserved Ejection Fraction Integrating Multiple Comorbidities.
- Author
-
Sharp TE 3rd, Scarborough AL, Li Z, Polhemus DJ, Hidalgo HA, Schumacher JD, Matsuura TR, Jenkins JS, Kelly DP, Goodchild TT, and Lefer DJ
- Abstract
A lack of preclinical large animal models of heart failure with preserved ejection fraction (HFpEF) that recapitulate this comorbid-laden syndrome has led to the inability to tease out mechanistic insights and to test novel therapeutic strategies. This study developed a large animal model that integrated multiple comorbid determinants of HFpEF in a miniswine breed that exhibited sensitivity to obesity, metabolic syndrome, and vascular disease with overt clinical signs of heart failure. The combination of a Western diet and 11-deoxycorticosterone acetate salt-induced hypertension in the Göttingen miniswine led to the development of a novel large animal model of HFpEF that exhibited multiorgan involvement and a full spectrum of comorbidities associated with human HFpEF., Competing Interests: Dr. Kelly is supported in part by the National Institutes of Health (R01 HL128349 and R01 HL151345). Dr. Matsuura is supported by the National Institute of Health (T32HL007843). Dr. Lefer was supported in part by the National Institutes of Health (1R01 HL146098, 1R56HL137711, 1R01 HL146514, and 1R01 HL151398). Drs. Sharp, Goodchild, and Lefer have a pending patent on the composition and methods for modeling HFpEF in Göttingen minipigs. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (© 2021 The Authors.)
- Published
- 2021
- Full Text
- View/download PDF
13. Endothelial Cell Cystathionine γ-Lyase Expression Level Modulates Exercise Capacity, Vascular Function, and Myocardial Ischemia Reperfusion Injury.
- Author
-
Xia H, Li Z, Sharp TE 3rd, Polhemus DJ, Carnal J, Moles KH, Tao YX, Elrod J, Pfeilschifter J, Beck KF, and Lefer DJ
- Subjects
- Animals, Aorta, Thoracic metabolism, Aorta, Thoracic physiopathology, Mice, Mice, Transgenic, Myocardium metabolism, Myocardium pathology, Nitric Oxide Synthase metabolism, Signal Transduction, Cystathionine gamma-Lyase metabolism, Endothelial Cells metabolism, Exercise Tolerance physiology, Hydrogen Sulfide metabolism, Myocardial Reperfusion Injury metabolism, Nitric Oxide metabolism
- Abstract
Background Hydrogen sulfide (H
2 S) is an important endogenous physiological signaling molecule and exerts protective properties in the cardiovascular system. Cystathionine γ-lyase (CSE), 1 of 3 H2 S producing enzyme, is predominantly localized in the vascular endothelium. However, the regulation of CSE in vascular endothelium remains incompletely understood. Methods and Results We generated inducible endothelial cell-specific CSE overexpressed transgenic mice (EC-CSE Tg) and endothelial cell-specific CSE knockout mice (EC-CSE KO), and investigated vascular function in isolated thoracic aorta, treadmill exercise capacity, and myocardial injury following ischemia-reperfusion in these mice. Overexpression of CSE in endothelial cells resulted in increased circulating and myocardial H2 S and NO, augmented endothelial-dependent vasorelaxation response in thoracic aorta, improved exercise capacity, and reduced myocardial-reperfusion injury. In contrast, genetic deletion of CSE in endothelial cells led to decreased circulating H2 S and cardiac NO production, impaired endothelial dependent vasorelaxation response and reduced exercise capacity. However, myocardial-reperfusion injury was not affected by genetic deletion of endothelial cell CSE. Conclusions CSE-derived H2 S production in endothelial cells is critical in maintaining endothelial function, exercise capacity, and protecting against myocardial ischemia/reperfusion injury. Our data suggest that the endothelial NO synthase-NO pathway is likely involved in the beneficial effects of overexpression of CSE in the endothelium.- Published
- 2020
- Full Text
- View/download PDF
14. Efficacy of a Novel Mitochondrial-Derived Peptide in a Porcine Model of Myocardial Ischemia/Reperfusion Injury.
- Author
-
Sharp TE 3rd, Gong Z, Scarborough A, Goetzman ES, Ali MJ, Spaletra P, Lefer DJ, Muzumdar RH, and Goodchild TT
- Abstract
With the complexities that surround myocardial ischemia/reperfusion (MI/R) injury, therapies adjunctive to reperfusion that elicit beneficial pleiotropic effects and do not overlap with standard of care are necessary. This study found that the mitochondrial-derived peptide S14G-humanin (HNG) (2 mg/kg), an analogue of humanin, reduced infarct size in a large animal model of MI/R. However, when ischemic time was increased, the infarct-sparing effects were abolished with the same dose of HNG. Thus, although the 60-min MI/R study showed that HNG cardioprotection translates beyond small animal models, further studies are needed to optimize HNG therapy for longer, more patient-relevant periods of cardiac ischemia., (© 2020 The Authors.)
- Published
- 2020
- Full Text
- View/download PDF
15. Nonlethal Inhibition of Gut Microbial Trimethylamine N-oxide Production Improves Cardiac Function and Remodeling in a Murine Model of Heart Failure.
- Author
-
Organ CL, Li Z, Sharp TE 3rd, Polhemus DJ, Gupta N, Goodchild TT, Tang WHW, Hazen SL, and Lefer DJ
- Subjects
- Animals, Bacteria enzymology, Bacterial Proteins antagonists & inhibitors, Bacterial Proteins metabolism, Choline metabolism, Disease Models, Animal, Down-Regulation, Fibrosis, Heart Failure microbiology, Heart Failure pathology, Heart Failure physiopathology, Lyases antagonists & inhibitors, Lyases metabolism, Male, Mice, Inbred C57BL, Myocardium pathology, Bacteria drug effects, Enzyme Inhibitors pharmacology, Gastrointestinal Microbiome drug effects, Heart Failure drug therapy, Intestines microbiology, Methylamines metabolism, Ventricular Function, Left drug effects, Ventricular Remodeling drug effects
- Abstract
Background Patients at increased risk for coronary artery disease and adverse prognosis during heart failure exhibit increased levels of circulating trimethylamine N-oxide (TMAO), a metabolite formed in the metabolism of dietary phosphatidylcholine. We investigated the efficacy of dietary withdrawal of TMAO as well as use of a gut microbe-targeted inhibitor of TMAO production, on cardiac function and structure during heart failure. Methods and Results Male C57BLK/6J mice were fed either control diet, a diet containing TMAO (0.12% wt/wt), a diet containing choline (1% wt/wt), or a diet containing choline (1% wt/wt) plus a microbial choline trimethylamine lyase inhibitor, iodomethylcholine (0.06% wt/wt), starting 3 weeks before transverse aortic constriction. At 6 weeks after transverse aortic constriction, a subset of animals in the TMAO group were switched to a control diet for the remainder of the study. Left ventricular structure and function were monitored at 3-week intervals. Withdrawal of TMAO from the diet attenuated adverse ventricular remodeling and improved cardiac function compared with the TMAO group. Similarly, inhibiting gut microbial conversion of choline to TMAO with a choline trimethylamine lyase inhibitor, iodomethylcholine, improved remodeling and cardiac function compared with the choline-fed group. Conclusions These experimental findings are clinically relevant, and they demonstrate that TMAO levels are modifiable following long-term exposure periods with either dietary withdrawal of TMAO or gut microbial blockade of TMAO generation. Furthermore, these therapeutic strategies to reduce circulating TMAO levels mitigate the negative effects of dietary choline and TMAO in heart failure.
- Published
- 2020
- Full Text
- View/download PDF
16. Cortical bone-derived stem cell therapy reduces apoptosis after myocardial infarction.
- Author
-
Hobby ARH, Sharp TE 3rd, Berretta RM, Borghetti G, Feldsott E, Mohsin S, and Houser SR
- Subjects
- Animals, Cells, Cultured, Disease Models, Animal, Female, Hematopoietic Stem Cells immunology, Hematopoietic Stem Cells metabolism, Leukocyte Common Antigens metabolism, Macrophages immunology, Macrophages metabolism, Male, Myocardial Infarction immunology, Myocardial Infarction metabolism, Myocardial Infarction pathology, Myocardial Reperfusion Injury metabolism, Myocardial Reperfusion Injury pathology, Myocytes, Cardiac immunology, Swine, Swine, Miniature, T-Lymphocytes immunology, T-Lymphocytes metabolism, Time Factors, Apoptosis, Myocardial Infarction surgery, Myocardial Reperfusion Injury surgery, Myocytes, Cardiac pathology, Stem Cell Transplantation, Stem Cells, Tibia cytology
- Abstract
Ischemic heart diseases such as myocardial infarction (MI) are the largest contributors to cardiovascular disease worldwide. The resulting cardiac cell death impairs function of the heart and can lead to heart failure and death. Reperfusion of the ischemic tissue is necessary but causes damage to the surrounding tissue by reperfusion injury. Cortical bone stem cells (CBSCs) have been shown to increase pump function and decrease scar size in a large animal swine model of MI. To investigate the potential mechanism for these changes, we hypothesized that CBSCs were altering cardiac cell death after reperfusion. To test this, we performed TUNEL staining for apoptosis and antibody-based immunohistochemistry on tissue from Göttingen miniswine that underwent 90 min of lateral anterior descending coronary artery ischemia followed by 3 or 7 days of reperfusion to assess changes in cardiomyocyte and noncardiomyocyte cell death. Our findings indicate that although myocyte apoptosis is present 3 days after ischemia and is lower in CBSC-treated animals, myocyte apoptosis accounts for <2% of all apoptosis in the reperfused heart. In addition, nonmyocyte apoptosis trends toward decreased in CBSC-treated hearts, and although CBSCs increase macrophage and T-cell populations in the infarct region, the occurrence of apoptosis in CD45
+ cells in the myocardium is not different between groups. From these data, we conclude that CBSCs may be influencing cardiomyocyte and noncardiomyocyte cell death and immune cell recruitment dynamics in the heart after MI, and these changes may account for some of the beneficial effects conferred by CBSC treatment. NEW & NOTEWORTHY The following research explores aspects of cell death and inflammation that have not been previously studied in a large animal model. In addition, apoptosis and cell death have not been studied in the context of cell therapy and myocardial infarction. In this article, we describe interactions between cell therapy and inflammation and the potential implications for cardiac wound healing.- Published
- 2019
- Full Text
- View/download PDF
17. Cardiometabolic Heart Failure and HFpEF: Still Chasing Unicorns.
- Author
-
Sharp TE 3rd, Lefer DJ, and Houser SR
- Published
- 2019
- Full Text
- View/download PDF
18. Repeated cell transplantation and adjunct renal denervation in ischemic heart failure: exploring modalities for improving cell therapy efficacy.
- Author
-
Polhemus DJ, Trivedi RK, Sharp TE, Li Z, Goodchild TT, Scarborough A, de Couto G, Marbán E, and Lefer DJ
- Subjects
- Animals, Heart Failure, Kidney innervation, Kidney surgery, Male, Myocardial Infarction, Rats, Rats, Inbred SHR, Rats, Inbred WKY, Ventricular Remodeling physiology, Autonomic Denervation methods, Myocardial Reperfusion Injury, Stem Cell Transplantation methods
- Abstract
Enthusiasm for cell therapy for myocardial injury has waned due to equivocal benefits in clinical trials. In an attempt to improve efficacy, we investigated repeated cell therapy and adjunct renal denervation (RDN) as strategies for augmenting cardioprotection with cardiosphere-derived cells (CDCs). We hypothesized that combining CDC post-conditioning with repeated CDC doses or delayed RDN therapy would result in superior function and remodeling. Wistar-Kyoto (WKY) rats or spontaneously hypertensive rats (SHR) were subjected to 45 min of coronary artery ligation followed by reperfusion for 12-14 weeks. In the first study arm, SHR were treated with CDCs (0.5 × 10
6 i.c.) or PBS 20 min following reperfusion, or additionally treated with CDCs (1.0 × 106 i.v.) at 2, 4, and 8 weeks. In the second arm, at 4 weeks following myocardial infarction (MI), SHR received CDCs (0.5 × 106 i.c.) or CDCs + RDN. In the third arm, WKY rats were treated with i.c. CDCs administered 20 min following reperfusion and RDN or a sham at 4 weeks. Early i.c. + multiple i.v. dosing, but not single i.c. dosing, of CDCs improved long-term left ventricular (LV) function, but not remodeling. Delayed CDC + RDN therapy was not superior to single-dose delayed CDC therapy. Early CDC + delayed RDN therapy improved LV ejection fraction and remodeling compared to both CDCs alone and RDN alone. Given that both RDN and CDCs are currently in the clinic, our findings motivate further translation targeting a heart failure indication with combined approaches.- Published
- 2019
- Full Text
- View/download PDF
19. Hydrogen Sulfide Attenuates Renin Angiotensin and Aldosterone Pathological Signaling to Preserve Kidney Function and Improve Exercise Tolerance in Heart Failure.
- Author
-
Li Z, Organ CL, Kang J, Polhemus DJ, Trivedi RK, Sharp TE 3rd, Jenkins JS, Tao YX, Xian M, and Lefer DJ
- Abstract
Cardioprotective effects of H
2 S have been well documented. However, the lack of evidence supporting the benefits afforded by delayed H2 S therapy warrants further investigation. Using a murine model of transverse aortic constriction-induced heart failure, this study showed that delayed H2 S therapy protects multiple organs including the heart, kidney, and blood-vessel; reduces oxidative stress; attenuates renal sympathetic and renin-angiotensin-aldosterone system pathological activation; and ultimately improves exercise capacity. These findings provide further insights into H2 S-mediated cardiovascular protection and implicate the benefits of using H2 S-based therapies clinically for the treatment of heart failure.- Published
- 2018
- Full Text
- View/download PDF
20. Renal Denervation Prevents Heart Failure Progression Via Inhibition of the Renin-Angiotensin System.
- Author
-
Sharp TE 3rd, Polhemus DJ, Li Z, Spaletra P, Jenkins JS, Reilly JP, White CJ, Kapusta DR, Lefer DJ, and Goodchild TT
- Subjects
- Animals, Dose-Response Relationship, Drug, Echocardiography methods, Female, Heart Failure metabolism, Kidney diagnostic imaging, Kidney metabolism, Kidney surgery, Renal Artery diagnostic imaging, Renal Artery innervation, Renal Artery metabolism, Renal Artery surgery, Renin-Angiotensin System drug effects, Swine, Swine, Miniature, Vasodilator Agents pharmacology, Ventricular Remodeling drug effects, Ventricular Remodeling physiology, Autonomic Denervation methods, Disease Progression, Heart Failure diagnostic imaging, Heart Failure prevention & control, Kidney innervation, Renin-Angiotensin System physiology
- Abstract
Background: Previously, we have shown that radiofrequency (RF) renal denervation (RDN) reduces myocardial infarct size in a rat model of acute myocardial infarction (MI) and improves left ventricular (LV) function and vascular reactivity in the setting of heart failure following MI., Objectives: The authors investigated the therapeutic efficacy of RF-RDN in a clinically relevant normotensive swine model of heart failure with reduced ejection fraction (HFrEF)., Methods: Yucatan miniswine underwent 75 min of left anterior descending coronary artery balloon occlusion to induce MI followed by reperfusion (R) for 18 weeks. Cardiac function was assessed pre- and post-MI/R by transthoracic echocardiography and every 3 weeks for 18 weeks. HFrEF was classified by an LV ejection fraction <40%. Animals who met inclusion criteria were randomized to receive bilateral RF-RDN (n = 10) treatment or sham-RDN (n = 11) at 6 weeks post-MI/R using an RF-RDN catheter., Results: RF-RDN therapy resulted in significant reductions in renal norepinephrine content and circulating angiotensin I and II. RF-RDN significantly increased circulating B-type natriuretic peptide levels. Following RF-RDN, LV end-systolic volume was significantly reduced when compared with sham-treated animals, leading to a marked and sustained improvement in LV ejection fraction. Furthermore, RF-RDN improved LV longitudinal strain. Simultaneously, RF-RDN reduced LV fibrosis and improved coronary artery responses to vasodilators., Conclusions: RF-RDN provides a novel therapeutic strategy to reduce renal sympathetic activity, inhibit the renin-angiotensin system, increase circulating B-type natriuretic peptide levels, attenuate LV fibrosis, and improve left ventricular performance and coronary vascular function. These cardioprotective mechanisms synergize to halt the progression of HFrEF following MI/R in a clinically relevant model system., (Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
21. Angiotensin Receptor-Neprilysin Inhibitors Emerge as Potential Treatment for Acute Myocardial Infarction.
- Author
-
Lefer DJ and Sharp TE 3rd
- Subjects
- Aminobutyrates, Animals, Biphenyl Compounds, Drug Combinations, Infarction, Rabbits, Receptors, Angiotensin, Tetrazoles, Valsartan, Ventricular Remodeling, Myocardial Infarction, Neprilysin
- Published
- 2018
- Full Text
- View/download PDF
22. A novel fibroblast activation inhibitor attenuates left ventricular remodeling and preserves cardiac function in heart failure.
- Author
-
Bradley JM, Spaletra P, Li Z, Sharp TE 3rd, Goodchild TT, Corral LG, Fung L, Chan KWH, Sullivan RW, Swindlehurst CA, and Lefer DJ
- Subjects
- Animals, Cardiotonic Agents therapeutic use, Cells, Cultured, Collagen metabolism, Humans, Male, Mice, Mice, Inbred C57BL, Myofibroblasts metabolism, Protein-Lysine 6-Oxidase metabolism, Proto-Oncogene Proteins c-akt metabolism, Ribosomal Protein S6 Kinases, 70-kDa metabolism, STAT3 Transcription Factor metabolism, Sulfonamides chemistry, Sulfonamides therapeutic use, Transforming Growth Factor beta metabolism, Cardiotonic Agents pharmacology, Heart Failure drug therapy, Myofibroblasts drug effects, Sulfonamides pharmacology, Ventricular Remodeling drug effects
- Abstract
Cardiac fibroblasts are critical mediators of fibrotic remodeling in the failing heart and transform into myofibroblasts in the presence of profibrotic factors such as transforming growth factor-β. Myocardial fibrosis worsens cardiac function, accelerating the progression to decompensated heart failure (HF). We investigated the effects of a novel inhibitor (NM922; NovoMedix, San Diego, CA) of the conversion of normal fibroblasts to the myofibroblast phenotype in the setting of pressure overload-induced HF. NM922 inhibited fibroblast-to-myofibroblast transformation in vitro via a reduction of activation of the focal adhesion kinase-Akt-p70S6 kinase and STAT3/4E-binding protein 1 pathways as well as via induction of cyclooxygenase-2. NM922 preserved left ventricular ejection fraction ( P < 0.05 vs. vehicle) and significantly attenuated transverse aortic constriction-induced LV dilation and hypertrophy ( P < 0.05 compared with vehicle). NM922 significantly ( P < 0.05) inhibited fibroblast activation, as evidenced by reduced myofibroblast counts per square millimeter of tissue area. Picrosirius red staining demonstrated that NM922 reduced ( P < 0.05) interstitial fibrosis compared with mice that received vehicle. Similarly, NM922 hearts had lower mRNA levels ( P < 0.05) of collagen types I and III, lysyl oxidase, and TNF-α at 16 wk after transverse aortic constriction. Treatment with NM922 after the onset of cardiac hypertrophy and HF resulted in attenuated myocardial collagen formation and adverse remodeling with preservation of left ventricular ejection fraction. Future studies are aimed at further elucidation of the molecular and cellular mechanisms by which this novel antifibrotic agent protects the failing heart. NEW & NOTEWORTHY Our data demonstrated that a novel antifibrotic agent, NM922, blocks the activation of fibroblasts, reduces the formation of cardiac fibrosis, and preserves cardiac function in a murine model of heart failure with reduced ejection fraction.
- Published
- 2018
- Full Text
- View/download PDF
23. Protein Kinase C Inhibition With Ruboxistaurin Increases Contractility and Reduces Heart Size in a Swine Model of Heart Failure With Reduced Ejection Fraction.
- Author
-
Sharp TE 3rd, Kubo H, Berretta RM, Starosta T, Wallner M, Schena GJ, Hobby AR, Yu D, Trappanese DM, George JC, Molkentin JD, and Houser SR
- Abstract
Inotropic support is often required to stabilize the hemodynamics of patients with acute decompensated heart failure; while efficacious, it has a history of leading to lethal arrhythmias and/or exacerbating contractile and energetic insufficiencies. Novel therapeutics that can improve contractility independent of beta-adrenergic and protein kinase A-regulated signaling, should be therapeutically beneficial. This study demonstrates that acute protein kinase C-α/β inhibition, with ruboxistaurin at 3 months' post-myocardial infarction, significantly increases contractility and reduces the end-diastolic/end-systolic volumes, documenting beneficial remodeling. These data suggest that ruboxistaurin represents a potential novel therapeutic for heart failure patients, as a moderate inotrope or therapeutic, which leads to beneficial ventricular remodeling.
- Published
- 2017
- Full Text
- View/download PDF
24. A Feline HFpEF Model with Pulmonary Hypertension and Compromised Pulmonary Function.
- Author
-
Wallner M, Eaton DM, Berretta RM, Borghetti G, Wu J, Baker ST, Feldsott EA, Sharp TE 3rd, Mohsin S, Oyama MA, von Lewinski D, Post H, Wolfson MR, and Houser SR
- Subjects
- Animals, Cats, Disease Models, Animal, Female, Fibrosis, Male, Myocytes, Cardiac metabolism, Myocytes, Cardiac pathology, Stroke Volume, Hypertension, Pulmonary blood, Hypertension, Pulmonary pathology, Hypertension, Pulmonary physiopathology, Hypertrophy, Left Ventricular blood, Hypertrophy, Left Ventricular pathology, Hypertrophy, Left Ventricular physiopathology, Pulmonary Alveoli blood supply, Pulmonary Alveoli metabolism, Pulmonary Alveoli pathology, Pulmonary Alveoli physiopathology, Ventricular Dysfunction, Left blood, Ventricular Dysfunction, Left pathology, Ventricular Dysfunction, Left physiopathology
- Abstract
Heart Failure with preserved Ejection Fraction (HFpEF) represents a major public health problem. The causative mechanisms are multifactorial and there are no effective treatments for HFpEF, partially attributable to the lack of well-established HFpEF animal models. We established a feline HFpEF model induced by slow-progressive pressure overload. Male domestic short hair cats (n = 20), underwent either sham procedures (n = 8) or aortic constriction (n = 12) with a customized pre-shaped band. Pulmonary function, gas exchange, and invasive hemodynamics were measured at 4-months post-banding. In banded cats, echocardiography at 4-months revealed concentric left ventricular (LV) hypertrophy, left atrial (LA) enlargement and dysfunction, and LV diastolic dysfunction with preserved systolic function, which subsequently led to elevated LV end-diastolic pressures and pulmonary hypertension. Furthermore, LV diastolic dysfunction was associated with increased LV fibrosis, cardiomyocyte hypertrophy, elevated NT-proBNP plasma levels, fluid and protein loss in pulmonary interstitium, impaired lung expansion, and alveolar-capillary membrane thickening. We report for the first time in HFpEF perivascular fluid cuff formation around extra-alveolar vessels with decreased respiratory compliance. Ultimately, these cardiopulmonary abnormalities resulted in impaired oxygenation. Our findings support the idea that this model can be used for testing novel therapeutic strategies to treat the ever growing HFpEF population.
- Published
- 2017
- Full Text
- View/download PDF
25. Combination Cell Therapy for Ischemic Cardiomyopathy: Is the Whole Greater Than Sum of Its Parts?
- Author
-
Recchia FA and Sharp TE 3rd
- Subjects
- Cell- and Tissue-Based Therapy, Humans, Regeneration, Stem Cells, Cardiomyopathies, Myocardial Ischemia
- Published
- 2017
- Full Text
- View/download PDF
26. Cortical Bone Stem Cell Therapy Preserves Cardiac Structure and Function After Myocardial Infarction.
- Author
-
Sharp TE 3rd, Schena GJ, Hobby AR, Starosta T, Berretta RM, Wallner M, Borghetti G, Gross P, Yu D, Johnson J, Feldsott E, Trappanese DM, Toib A, Rabinowitz JE, George JC, Kubo H, Mohsin S, and Houser SR
- Subjects
- Animals, Apoptosis, Arrhythmias, Cardiac physiopathology, Arrhythmias, Cardiac prevention & control, Cell Proliferation, Cells, Cultured, Disease Models, Animal, Female, Hemodynamics, Myocardial Contraction, Myocardial Infarction pathology, Myocardial Infarction physiopathology, Myocardial Reperfusion Injury pathology, Myocardial Reperfusion Injury physiopathology, Phenotype, Stroke Volume, Sus scrofa, Time Factors, Cortical Bone cytology, Myocardial Infarction surgery, Myocardial Reperfusion Injury surgery, Myocardium pathology, Stem Cells physiology, Ventricular Function, Left, Ventricular Remodeling
- Abstract
Rationale: Cortical bone stem cells (CBSCs) have been shown to reduce ventricular remodeling and improve cardiac function in a murine myocardial infarction (MI) model. These effects were superior to other stem cell types that have been used in recent early-stage clinical trials. However, CBSC efficacy has not been tested in a preclinical large animal model using approaches that could be applied to patients., Objective: To determine whether post-MI transendocardial injection of allogeneic CBSCs reduces pathological structural and functional remodeling and prevents the development of heart failure in a swine MI model., Methods and Results: Female Göttingen swine underwent left anterior descending coronary artery occlusion, followed by reperfusion (ischemia-reperfusion MI). Animals received, in a randomized, blinded manner, 1:1 ratio, CBSCs (n=9; 2×10
7 cells total) or placebo (vehicle; n=9) through NOGA-guided transendocardial injections. 5-ethynyl-2'deoxyuridine (EdU)-a thymidine analog-containing minipumps were inserted at the time of MI induction. At 72 hours (n=8), initial injury and cell retention were assessed. At 3 months post-MI, cardiac structure and function were evaluated by serial echocardiography and terminal invasive hemodynamics. CBSCs were present in the MI border zone and proliferating at 72 hours post-MI but had no effect on initial cardiac injury or structure. At 3 months, CBSC-treated hearts had significantly reduced scar size, smaller myocytes, and increased myocyte nuclear density. Noninvasive echocardiographic measurements showed that left ventricular volumes and ejection fraction were significantly more preserved in CBSC-treated hearts, and invasive hemodynamic measurements documented improved cardiac structure and functional reserve. The number of EdU+ cardiac myocytes was increased in CBSC- versus vehicle- treated animals., Conclusions: CBSC administration into the MI border zone reduces pathological cardiac structural and functional remodeling and improves left ventricular functional reserve. These effects reduce those processes that can lead to heart failure with reduced ejection fraction., (© 2017 American Heart Association, Inc.)- Published
- 2017
- Full Text
- View/download PDF
27. Remodeling of repolarization and arrhythmia susceptibility in a myosin-binding protein C knockout mouse model.
- Author
-
Toib A, Zhang C, Borghetti G, Zhang X, Wallner M, Yang Y, Troupes CD, Kubo H, Sharp TE, Feldsott E, Berretta RM, Zalavadia N, Trappanese DM, Harper S, Gross P, Chen X, Mohsin S, and Houser SR
- Subjects
- Action Potentials, Animals, Cardiomegaly genetics, Cardiomegaly metabolism, Cardiomegaly pathology, Carrier Proteins genetics, Disease Models, Animal, Electrocardiography, Ambulatory, Fibrosis, Genetic Predisposition to Disease, Kinetics, Male, Mice, 129 Strain, Mice, Knockout, Myocardial Contraction, Myocytes, Cardiac pathology, Patch-Clamp Techniques, Phenotype, Potassium Channels genetics, RNA, Messenger genetics, RNA, Messenger metabolism, Tachycardia, Ventricular genetics, Tachycardia, Ventricular pathology, Tachycardia, Ventricular physiopathology, Telemetry, Ventricular Premature Complexes genetics, Ventricular Premature Complexes pathology, Ventricular Premature Complexes physiopathology, Carrier Proteins metabolism, Heart Rate, Myocytes, Cardiac metabolism, Potassium metabolism, Potassium Channels metabolism, Tachycardia, Ventricular metabolism, Ventricular Premature Complexes metabolism
- Abstract
Hypertrophic cardiomyopathy (HCM) is one of the most common genetic cardiac diseases and among the leading causes of sudden cardiac death (SCD) in the young. The cellular mechanisms leading to SCD in HCM are not well known. Prolongation of the action potential (AP) duration (APD) is a common feature predisposing hypertrophied hearts to SCD. Previous studies have explored the roles of inward Na
+ and Ca2+ in the development of HCM, but the role of repolarizing K+ currents has not been defined. The objective of this study was to characterize the arrhythmogenic phenotype and cellular electrophysiological properties of mice with HCM, induced by myosin-binding protein C (MyBPC) knockout (KO), and to test the hypothesis that remodeling of repolarizing K+ currents causes APD prolongation in MyBPC KO myocytes. We demonstrated that MyBPC KO mice developed severe hypertrophy and cardiac dysfunction compared with wild-type (WT) control mice. Telemetric electrocardiographic recordings of awake mice revealed prolongation of the corrected QT interval in the KO compared with WT control mice, with overt ventricular arrhythmias. Whole cell current- and voltage-clamp experiments comparing KO with WT mice demonstrated ventricular myocyte hypertrophy, AP prolongation, and decreased repolarizing K+ currents. Quantitative RT-PCR analysis revealed decreased mRNA levels of several key K+ channel subunits. In conclusion, decrease in repolarizing K+ currents in MyBPC KO ventricular myocytes contributes to AP and corrected QT interval prolongation and could account for the arrhythmia susceptibility. NEW & NOTEWORTHY Ventricular myocytes isolated from the myosin-binding protein C knockout hypertrophic cardiomyopathy mouse model demonstrate decreased repolarizing K+ currents and action potential and QT interval prolongation, linking cellular repolarization abnormalities with arrhythmia susceptibility and the risk for sudden cardiac death in hypertrophic cardiomyopathy., (Copyright © 2017 the American Physiological Society.)- Published
- 2017
- Full Text
- View/download PDF
28. Acute right heart failure after hemorrhagic shock and trauma pneumonectomy-a management approach: A blinded randomized controlled animal trial using inhaled nitric oxide.
- Author
-
Lubitz AL, Sjoholm LO, Goldberg A, Pathak A, Santora T, Sharp TE 3rd, Wallner M, Berretta RM, Poole LA, Wu J, and Wolfson MR
- Subjects
- Administration, Inhalation, Animals, Blood Chemical Analysis, Blood Transfusion, Autologous, Disease Models, Animal, Echocardiography, Hemodynamics, Nitric Oxide administration & dosage, Pulmonary Gas Exchange, Sheep, Sternotomy, Vascular Resistance drug effects, Heart Failure prevention & control, Nitric Oxide pharmacology, Pneumonectomy, Pulmonary Artery drug effects, Shock, Hemorrhagic physiopathology, Ventricular Dysfunction, Right prevention & control
- Abstract
Background: Hemorrhagic shock and pneumonectomy causes an acute increase in pulmonary vascular resistance (PVR). The increase in PVR and right ventricular (RV) afterload leads to acute RV failure, thus reducing left ventricular (LV) preload and output. Inhaled nitric oxide (iNO) lowers PVR by relaxing pulmonary arterial smooth muscle without remarkable systemic vascular effects. We hypothesized that with hemorrhagic shock and pneumonectomy, iNO can be used to decrease PVR and mitigate right heart failure., Methods: A hemorrhagic shock and pneumonectomy model was developed using sheep. Sheep received lung protective ventilatory support and were instrumented to serially obtain measurements of hemodynamics, gas exchange, and blood chemistry. Heart function was assessed with echocardiography. After randomization to study gas of iNO 20 ppm (n = 9) or nitrogen as placebo (n = 9), baseline measurements were obtained. Hemorrhagic shock was initiated by exsanguination to a target of 50% of the baseline mean arterial pressure. The resuscitation phase was initiated, consisting of simultaneous left pulmonary hilum ligation, via median sternotomy, infusion of autologous blood and initiation of study gas. Animals were monitored for 4 hours., Results: All animals had an initial increase in PVR. PVR remained elevated with placebo; with iNO, PVR decreased to baseline. Echo showed improved RV function in the iNO group while it remained impaired in the placebo group. After an initial increase in shunt and lactate and decrease in SvO2, all returned toward baseline in the iNO group but remained abnormal in the placebo group., Conclusion: These data indicate that by decreasing PVR, iNO decreased RV afterload, preserved RV and LV function, and tissue oxygenation in this hemorrhagic shock and pneumonectomy model. This suggests that iNO may be a useful clinical adjunct to mitigate right heart failure and improve survival when trauma pneumonectomy is required.
- Published
- 2017
- Full Text
- View/download PDF
29. Acute Catecholamine Exposure Causes Reversible Myocyte Injury Without Cardiac Regeneration.
- Author
-
Wallner M, Duran JM, Mohsin S, Troupes CD, Vanhoutte D, Borghetti G, Vagnozzi RJ, Gross P, Yu D, Trappanese DM, Kubo H, Toib A, Sharp TE 3rd, Harper SC, Volkert MA, Starosta T, Feldsott EA, Berretta RM, Wang T, Barbe MF, Molkentin JD, and Houser SR
- Subjects
- Animals, Catecholamines administration & dosage, Catecholamines toxicity, Male, Mice, Mice, Inbred C57BL, Mice, Transgenic, Myocytes, Cardiac physiology, Regeneration physiology, Isoproterenol administration & dosage, Isoproterenol toxicity, Myocytes, Cardiac drug effects, Myocytes, Cardiac pathology, Regeneration drug effects
- Abstract
Rationale: Catecholamines increase cardiac contractility, but exposure to high concentrations or prolonged exposures can cause cardiac injury. A recent study demonstrated that a single subcutaneous injection of isoproterenol (ISO; 200 mg/kg) in mice causes acute myocyte death (8%-10%) with complete cardiac repair within a month. Cardiac regeneration was via endogenous cKit(+) cardiac stem cell-mediated new myocyte formation., Objective: Our goal was to validate this simple injury/regeneration system and use it to study the biology of newly forming adult cardiac myocytes., Methods and Results: C57BL/6 mice (n=173) were treated with single injections of vehicle, 200 or 300 mg/kg ISO, or 2 daily doses of 200 mg/kg ISO for 6 days. Echocardiography revealed transiently increased systolic function and unaltered diastolic function 1 day after single ISO injection. Single ISO injections also caused membrane injury in ≈10% of myocytes, but few of these myocytes appeared to be necrotic. Circulating troponin I levels after ISO were elevated, further documenting myocyte damage. However, myocyte apoptosis was not increased after ISO injury. Heart weight to body weight ratio and fibrosis were also not altered 28 days after ISO injection. Single- or multiple-dose ISO injury was not associated with an increase in the percentage of 5-ethynyl-2'-deoxyuridine-labeled myocytes. Furthermore, ISO injections did not increase new myocytes in cKit(+/Cre)×R-GFP transgenic mice., Conclusions: A single dose of ISO causes injury in ≈10% of the cardiomyocytes. However, most of these myocytes seem to recover and do not elicit cKit(+) cardiac stem cell-derived myocyte regeneration., (© 2016 American Heart Association, Inc.)
- Published
- 2016
- Full Text
- View/download PDF
30. Nuquantus: Machine learning software for the characterization and quantification of cell nuclei in complex immunofluorescent tissue images.
- Author
-
Gross P, Honnorat N, Varol E, Wallner M, Trappanese DM, Sharp TE, Starosta T, Duran JM, Koller S, Davatzikos C, and Houser SR
- Subjects
- Animals, Cell Proliferation, Cell Survival, Humans, Microscopy, Confocal, Myocytes, Cardiac metabolism, Cell Nucleus metabolism, Fluorescent Antibody Technique methods, Image Processing, Computer-Assisted methods, Machine Learning, Myocytes, Cardiac cytology, Software
- Abstract
Determination of fundamental mechanisms of disease often hinges on histopathology visualization and quantitative image analysis. Currently, the analysis of multi-channel fluorescence tissue images is primarily achieved by manual measurements of tissue cellular content and sub-cellular compartments. Since the current manual methodology for image analysis is a tedious and subjective approach, there is clearly a need for an automated analytical technique to process large-scale image datasets. Here, we introduce Nuquantus (Nuclei quantification utility software) - a novel machine learning-based analytical method, which identifies, quantifies and classifies nuclei based on cells of interest in composite fluorescent tissue images, in which cell borders are not visible. Nuquantus is an adaptive framework that learns the morphological attributes of intact tissue in the presence of anatomical variability and pathological processes. Nuquantus allowed us to robustly perform quantitative image analysis on remodeling cardiac tissue after myocardial infarction. Nuquantus reliably classifies cardiomyocyte versus non-cardiomyocyte nuclei and detects cell proliferation, as well as cell death in different cell classes. Broadly, Nuquantus provides innovative computerized methodology to analyze complex tissue images that significantly facilitates image analysis and minimizes human bias.
- Published
- 2016
- Full Text
- View/download PDF
31. Unique Features of Cortical Bone Stem Cells Associated With Repair of the Injured Heart.
- Author
-
Mohsin S, Troupes CD, Starosta T, Sharp TE, Agra EJ, Smith S, Duran JM, Zalavadia N, Zhou Y, Kubo H, Berretta RM, and Houser SR
- Subjects
- Animals, Cats, Cell Differentiation physiology, Cells, Cultured, Coculture Techniques, Female, Heart Diseases pathology, Mice, Mice, Inbred C57BL, Mice, Transgenic, Myocytes, Cardiac physiology, Myocytes, Cardiac transplantation, Swine, Swine, Miniature, Heart Diseases therapy, Mesenchymal Stem Cell Transplantation methods, Mesenchymal Stem Cells physiology
- Abstract
Rationale: Adoptive transfer of multiple stem cell types has only had modest effects on the structure and function of failing human hearts. Despite increasing the use of stem cell therapies, consensus on the optimal stem cell type is not adequately defined. The modest cardiac repair and functional improvement in patients with cardiac disease warrants identification of a novel stem cell population that possesses properties that induce a more substantial improvement in patients with heart failure., Objective: To characterize and compare surface marker expression, proliferation, survival, migration, and differentiation capacity of cortical bone stem cells (CBSCs) relative to mesenchymal stem cells (MSCs) and cardiac-derived stem cells (CDCs), which have already been tested in early stage clinical trials., Methods and Results: CBSCs, MSCs, and CDCs were isolated from Gottingen miniswine or transgenic C57/BL6 mice expressing enhanced green fluorescent protein and were expanded in vitro. CBSCs possess a unique surface marker profile, including high expression of CD61 and integrin β4 versus CDCs and MSCs. In addition, CBSCs were morphologically distinct and showed enhanced proliferation capacity versus CDCs and MSCs. CBSCs had significantly better survival after exposure to an apoptotic stimuli when compared with MSCs. ATP and histamine induced a transient increase of intracellular Ca(2+) concentration in CBSCs versus CDCs and MSCs, which either respond to ATP or histamine only further documenting the differences between the 3 cell types., Conclusions: CBSCs are unique from CDCs and MSCs and possess enhanced proliferative, survival, and lineage commitment capacity that could account for the enhanced protective effects after cardiac injury., (© 2015 American Heart Association, Inc.)
- Published
- 2015
- Full Text
- View/download PDF
32. Autologous c-Kit+ Mesenchymal Stem Cell Injections Provide Superior Therapeutic Benefit as Compared to c-Kit+ Cardiac-Derived Stem Cells in a Feline Model of Isoproterenol-Induced Cardiomyopathy.
- Author
-
Taghavi S, Sharp TE 3rd, Duran JM, Makarewich CA, Berretta RM, Starosta T, Kubo H, Barbe M, and Houser SR
- Subjects
- Animals, Biomarkers metabolism, Cardiomyopathies chemically induced, Cardiomyopathies metabolism, Cardiomyopathies pathology, Cardiomyopathies physiopathology, Cats, Cell Proliferation, Cells, Cultured, Disease Models, Animal, Fibrosis, Myocardial Contraction, Myocytes, Cardiac pathology, Recovery of Function, Stroke Volume, Time Factors, Transplantation, Autologous, Ventricular Function, Left, Ventricular Pressure, Ventricular Remodeling, Cardiomyopathies surgery, Isoproterenol, Mesenchymal Stem Cell Transplantation, Mesenchymal Stem Cells metabolism, Myocytes, Cardiac metabolism, Myocytes, Cardiac transplantation, Proto-Oncogene Proteins c-kit metabolism, Regeneration
- Abstract
Background: Cardiac- (CSC) and mesenchymal-derived (MSC) CD117+ isolated stem cells improve cardiac function after injury. However, no study has compared the therapeutic benefit of these cells when used autologously., Methods: MSCs and CSCs were isolated on day 0. Cardiomyopathy was induced (day 28) by infusion of L-isoproterenol (1,100 ug/kg/hour) from Alzet minipumps for 10 days. Bromodeoxyuridine (BrdU) was infused via minipumps (50 mg/mL) to identify proliferative cells during the injury phase. Following injury (day 38), autologous CSC (n = 7) and MSC (n = 4) were delivered by intracoronary injection. These animals were compared to those receiving sham injections by echocardiography, invasive hemodynamics, and immunohistochemistry., Results: Fractional shortening improved with CSC (26.9 ± 1.1% vs. 16.1 ± 0.2%, p = 0.01) and MSC (25.1 ± 0.2% vs. 12.1 ± 0.5%, p = 0.01) as compared to shams. MSC were superior to CSC in improving left ventricle end-diastolic (LVED) volume (37.7 ± 3.1% vs. 19.9 ± 9.4%, p = 0.03) and ejection fraction (27.7 ± 0.1% vs. 19.9 ± 0.4%, p = 0.02). LVED pressure was less in MSC (6.3 ± 1.3 mmHg) as compared to CSC (9.3 ± 0.7 mmHg) and sham (13.3 ± 0.7); p = 0.01. LV BrdU+ myocytes were higher in MSC (0.17 ± 0.03%) than CSC (0.09 ± 0.01%) and sham (0.06 ± 01%); p < 0.001., Conclusions: Both CD117+ isolated CSC and MSC therapy improve cardiac function and attenuate pathological remodeling. However, MSC appear to confer additional benefit., (© 2015 Wiley Periodicals, Inc.)
- Published
- 2015
- Full Text
- View/download PDF
33. BAG3: a new player in the heart failure paradigm.
- Author
-
Knezevic T, Myers VD, Gordon J, Tilley DG, Sharp TE 3rd, Wang J, Khalili K, Cheung JY, and Feldman AM
- Subjects
- Animals, Heart, Humans, Mutation, Adaptor Proteins, Signal Transducing genetics, Apoptosis genetics, Apoptosis Regulatory Proteins genetics, Autophagy genetics, Heart Failure genetics
- Abstract
BAG3 is a cellular protein that is expressed predominantly in skeletal and cardiac muscle but can also be found in the brain and in the peripheral nervous system. BAG3 functions in the cell include: serving as a co-chaperone with members of the heat-shock protein family of proteins to facilitate the removal of misfolded and degraded proteins, inhibiting apoptosis by interacting with Bcl2 and maintaining the structural integrity of the Z-disk in muscle by binding with CapZ. The importance of BAG3 in the homeostasis of myocytes and its role in the development of heart failure was evidenced by the finding that single allelic mutations in BAG3 were associated with familial dilated cardiomyopathy. Furthermore, significant decreases in the level of BAG3 have been found in end-stage failing human heart and in animal models of heart failure including mice with heart failure secondary to trans-aortic banding and in pigs after myocardial infarction. Thus, it becomes relevant to understand the cellular biology and molecular regulation of BAG3 expression in order to design new therapies for the treatment of patients with both hereditary and non-hereditary forms of dilated cardiomyopathy.
- Published
- 2015
- Full Text
- View/download PDF
34. Stem cell therapy and breast cancer treatment: review of stem cell research and potential therapeutic impact against cardiotoxicities due to breast cancer treatment.
- Author
-
Sharp TE 3rd and George JC
- Abstract
A new problem has emerged with the ever-increasing number of breast cancer survivors. While early screening and advances in treatment have allowed these patients to overcome their cancer, these treatments often have adverse cardiovascular side effects that can produce abnormal cardiovascular function. Chemotherapeutic and radiation therapy have both been linked to cardiotoxicity; these therapeutics can cause a loss of cardiac muscle and deterioration of vascular structure that can eventually lead to heart failure (HF). This cardiomyocyte toxicity can leave the breast cancer survivor with a probable diagnosis of dilated or restrictive cardiomyopathy (DCM or RCM). While current HF standard of care can alleviate symptoms, other than heart transplantation, there is no therapy that replaces cardiac myocytes that are killed during cancer therapies. There is a need to develop novel therapeutics that can either prevent or reverse the cardiac injury caused by cancer therapeutics. These new therapeutics should promote the regeneration of lost or deteriorating myocardium. Over the last several decades, the therapeutic potential of cell-based therapy has been investigated for HF patients. In this review, we discuss the progress of pre-clinical and clinical stem cell research for the diseased heart and discuss the possibility of utilizing these novel therapies to combat cardiotoxicity observed in breast cancer survivors.
- Published
- 2014
- Full Text
- View/download PDF
35. Sorafenib cardiotoxicity increases mortality after myocardial infarction.
- Author
-
Duran JM, Makarewich CA, Trappanese D, Gross P, Husain S, Dunn J, Lal H, Sharp TE, Starosta T, Vagnozzi RJ, Berretta RM, Barbe M, Yu D, Gao E, Kubo H, Force T, and Houser SR
- Subjects
- Animals, Apoptosis drug effects, Cats, Cell Proliferation drug effects, Cells, Cultured, Disease Models, Animal, Dose-Response Relationship, Drug, In Vitro Techniques, Male, Metoprolol pharmacology, Mice, Mice, Inbred C57BL, Myocardial Infarction pathology, Myocytes, Cardiac drug effects, Myocytes, Cardiac pathology, Niacinamide adverse effects, Niacinamide pharmacology, Proto-Oncogene Proteins c-kit drug effects, Proto-Oncogene Proteins c-kit metabolism, Sorafenib, Antineoplastic Agents adverse effects, Antineoplastic Agents pharmacology, Heart drug effects, Myocardial Infarction mortality, Niacinamide analogs & derivatives, Phenylurea Compounds adverse effects, Phenylurea Compounds pharmacology
- Abstract
Rationale: Sorafenib is an effective treatment for renal cell carcinoma, but recent clinical reports have documented its cardiotoxicity through an unknown mechanism., Objective: Determining the mechanism of sorafenib-mediated cardiotoxicity., Methods and Results: Mice treated with sorafenib or vehicle for 3 weeks underwent induced myocardial infarction (MI) after 1 week of treatment. Sorafenib markedly decreased 2-week survival relative to vehicle-treated controls, but echocardiography at 1 and 2 weeks post MI detected no differences in cardiac function. Sorafenib-treated hearts had significantly smaller diastolic and systolic volumes and reduced heart weights. High doses of sorafenib induced necrotic death of isolated myocytes in vitro, but lower doses did not induce myocyte death or affect inotropy. Histological analysis documented increased myocyte cross-sectional area despite smaller heart sizes after sorafenib treatment, further suggesting myocyte loss. Sorafenib caused apoptotic cell death of cardiac- and bone-derived c-kit+ stem cells in vitro and decreased the number of BrdU+ (5-bromo-2'-deoxyuridine+) myocytes detected at the infarct border zone in fixed tissues. Sorafenib had no effect on infarct size, fibrosis, or post-MI neovascularization. When sorafenib-treated animals received metoprolol treatment post MI, the sorafenib-induced increase in post-MI mortality was eliminated, cardiac function was improved, and myocyte loss was ameliorated., Conclusions: Sorafenib cardiotoxicity results from myocyte necrosis rather than from any direct effect on myocyte function. Surviving myocytes undergo pathological hypertrophy. Inhibition of c-kit+ stem cell proliferation by inducing apoptosis exacerbates damage by decreasing endogenous cardiac repair. In the setting of MI, which also causes large-scale cell loss, sorafenib cardiotoxicity dramatically increases mortality., (© 2014 American Heart Association, Inc.)
- Published
- 2014
- Full Text
- View/download PDF
36. Bone-derived stem cells repair the heart after myocardial infarction through transdifferentiation and paracrine signaling mechanisms.
- Author
-
Duran JM, Makarewich CA, Sharp TE, Starosta T, Zhu F, Hoffman NE, Chiba Y, Madesh M, Berretta RM, Kubo H, and Houser SR
- Subjects
- Angiogenic Proteins biosynthesis, Angiogenic Proteins genetics, Angiogenic Proteins metabolism, Animals, Antigens, Ly biosynthesis, Antigens, Ly genetics, Biomarkers, Cells, Cultured cytology, Cells, Cultured metabolism, Gene Expression Regulation, Genes, Reporter, Membrane Proteins biosynthesis, Membrane Proteins genetics, Mice, Mice, Inbred C57BL, Mice, Transgenic, Multipotent Stem Cells cytology, Multipotent Stem Cells metabolism, Multipotent Stem Cells transplantation, Myocardial Infarction pathology, Neovascularization, Physiologic genetics, Proto-Oncogene Proteins c-kit biosynthesis, Proto-Oncogene Proteins c-kit genetics, Ventricular Remodeling physiology, Bone and Bones cytology, Cell Transdifferentiation, Endothelial Cells cytology, Multipotent Stem Cells physiology, Myocardial Infarction physiopathology, Myocytes, Cardiac cytology, Paracrine Communication physiology
- Abstract
Rationale: Autologous bone marrow-derived or cardiac-derived stem cell therapy for heart disease has demonstrated safety and efficacy in clinical trials, but functional improvements have been limited. Finding the optimal stem cell type best suited for cardiac regeneration is the key toward improving clinical outcomes., Objective: To determine the mechanism by which novel bone-derived stem cells support the injured heart., Methods and Results: Cortical bone-derived stem cells (CBSCs) and cardiac-derived stem cells were isolated from enhanced green fluorescent protein (EGFP+) transgenic mice and were shown to express c-kit and Sca-1 as well as 8 paracrine factors involved in cardioprotection, angiogenesis, and stem cell function. Wild-type C57BL/6 mice underwent sham operation (n=21) or myocardial infarction with injection of CBSCs (n=67), cardiac-derived stem cells (n=36), or saline (n=60). Cardiac function was monitored using echocardiography. Only 2/8 paracrine factors were detected in EGFP+ CBSCs in vivo (basic fibroblast growth factor and vascular endothelial growth factor), and this expression was associated with increased neovascularization of the infarct border zone. CBSC therapy improved survival, cardiac function, regional strain, attenuated remodeling, and decreased infarct size relative to cardiac-derived stem cells- or saline-treated myocardial infarction controls. By 6 weeks, EGFP+ cardiomyocytes, vascular smooth muscle, and endothelial cells could be identified in CBSC-treated, but not in cardiac-derived stem cells-treated, animals. EGFP+ CBSC-derived isolated myocytes were smaller and more frequently mononucleated, but were functionally indistinguishable from EGFP- myocytes., Conclusions: CBSCs improve survival, cardiac function, and attenuate remodeling through the following 2 mechanisms: (1) secretion of proangiogenic factors that stimulate endogenous neovascularization, and (2) differentiation into functional adult myocytes and vascular cells.
- Published
- 2013
- Full Text
- View/download PDF
37. Validation of transcatheter left ventricular electromechanical mapping for assessment of cardiac function and targeted transendocardial injection in a porcine ischemia-reperfusion model.
- Author
-
Taghavi S, Duran JM, Berretta RM, Makarewich CA, Udeshi F, Sharp TE, Kubo H, Houser SR, and George JC
- Abstract
Ischemic heart disease, despite advances in treatment, remains the major cause of mortality worldwide. NOGA 3D left ventricular electromechanical mapping allows accurate determination of cardiac function and precise identification of sites of injury. In a porcine model of ischemia-reperfusion injury, we validate the use of the NOGA mapping system for assessment of cardiac function along with the Myostar injection catheter for directed delivery of therapeutics to localized target sites in the setting of acute myocardial injury.
- Published
- 2012
38. Analysis of lens and zone plate combinations for achromatic focusing of ultrashort laser pulses.
- Author
-
Sharp TE and Wisoff PJ
- Abstract
Analysis of a combination zone plate and lens system is presented for the design of optical systems to focus ultrashort laser pulses. A system design that is free of propagation-time delay distortion and chromatic aberration is presented.
- Published
- 1992
- Full Text
- View/download PDF
39. Dispersion measurements of single-mode fibers in the blue-green spectral region by an interferometric method.
- Author
-
Szabó G, Sharp TE, Tittel FK, and Wisoff PJ
- Abstract
The chromatic dispersion of a single-mode, polarizationpreserving fiber in the blue-green spectral region was measured by using an interferometric method.
- Published
- 1991
- Full Text
- View/download PDF
40. Ultrashort-laser-pulse amplification in a XeF[C --> A] excimer amplifier.
- Author
-
Sharp TE, Hofmann T, Dane CB, Wilson WL Jr, Tittel FK, Wisoff PJ, and Szabó G
- Abstract
Tunable blue-green subpicosecond laser pulses have been amplified in an electron-beam-pumped XeF(C --> A) excimer amplifier. Small-signal gains of 3.5% cm(-1) were measured using a 50-cm active gain length. At output energy densities as high as 170 mJ/cm(2), only a small degree of saturation occurred, resulting in a gain of 2.5% cm(-1).
- Published
- 1990
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.